COVID-19 as a catalyst for vaccine manufacturing: A South African experience

COVID-19 highlighted inequitable vaccine distribution and the urgent need for vaccine manufacturing capacity on the African continent. This resulted in a burst of scientific engagement and international funding to augment capacity on the continent. However, short-term investment needs to be reinforc...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Penny L., Gray, Glenda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265761/
https://www.ncbi.nlm.nih.gov/pubmed/37321166
http://dx.doi.org/10.1016/j.chom.2023.05.015
_version_ 1785058600143552512
author Moore, Penny L.
Gray, Glenda
author_facet Moore, Penny L.
Gray, Glenda
author_sort Moore, Penny L.
collection PubMed
description COVID-19 highlighted inequitable vaccine distribution and the urgent need for vaccine manufacturing capacity on the African continent. This resulted in a burst of scientific engagement and international funding to augment capacity on the continent. However, short-term investment needs to be reinforced by a robust, strategic long-term plan to ensure sustainability.
format Online
Article
Text
id pubmed-10265761
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-102657612023-06-14 COVID-19 as a catalyst for vaccine manufacturing: A South African experience Moore, Penny L. Gray, Glenda Cell Host Microbe Commentary COVID-19 highlighted inequitable vaccine distribution and the urgent need for vaccine manufacturing capacity on the African continent. This resulted in a burst of scientific engagement and international funding to augment capacity on the continent. However, short-term investment needs to be reinforced by a robust, strategic long-term plan to ensure sustainability. Elsevier Inc. 2023-06-14 2023-06-14 /pmc/articles/PMC10265761/ /pubmed/37321166 http://dx.doi.org/10.1016/j.chom.2023.05.015 Text en © 2023 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Commentary
Moore, Penny L.
Gray, Glenda
COVID-19 as a catalyst for vaccine manufacturing: A South African experience
title COVID-19 as a catalyst for vaccine manufacturing: A South African experience
title_full COVID-19 as a catalyst for vaccine manufacturing: A South African experience
title_fullStr COVID-19 as a catalyst for vaccine manufacturing: A South African experience
title_full_unstemmed COVID-19 as a catalyst for vaccine manufacturing: A South African experience
title_short COVID-19 as a catalyst for vaccine manufacturing: A South African experience
title_sort covid-19 as a catalyst for vaccine manufacturing: a south african experience
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265761/
https://www.ncbi.nlm.nih.gov/pubmed/37321166
http://dx.doi.org/10.1016/j.chom.2023.05.015
work_keys_str_mv AT moorepennyl covid19asacatalystforvaccinemanufacturingasouthafricanexperience
AT grayglenda covid19asacatalystforvaccinemanufacturingasouthafricanexperience

Ejemplares similares